207 related articles for article (PubMed ID: 29057700)
1. Polymorphic lymphoproliferative disorders in patients with rheumatoid arthritis are associated with a better clinical outcome.
Tsukui D; Kanda H; Shinozaki-Ushiku A; Tateishi S; Takeshima Y; Nagafuchi Y; Sasaki O; Iwasaki Y; Harada H; Shibuya M; Sumitomo S; Shoda H; Kubo K; Fujio K; Nakamura F; Kurokawa M; Fukayama M; Yamamoto K
Mod Rheumatol; 2018 Jul; 28(4):621-625. PubMed ID: 29057700
[TBL] [Abstract][Full Text] [Related]
2. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders.
Yamakawa N; Fujimoto M; Kawabata D; Terao C; Nishikori M; Nakashima R; Imura Y; Yukawa N; Yoshifuji H; Ohmura K; Fujii T; Kitano T; Kondo T; Yurugi K; Miura Y; Maekawa T; Saji H; Takaori-Kondo A; Matsuda F; Haga H; Mimori T
J Rheumatol; 2014 Feb; 41(2):293-9. PubMed ID: 24334644
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.
Katsuyama T; Sada KE; Yan M; Zeggar S; Hiramatsu S; Miyawaki Y; Ohashi K; Morishita M; Watanabe H; Katsuyama E; Takano-Narazaki M; Toyota-Tatebe N; Sunahori-Watanabe K; Kawabata T; Miyake K; Kiguchi T; Wada J
Mod Rheumatol; 2017 Sep; 27(5):773-777. PubMed ID: 27846761
[TBL] [Abstract][Full Text] [Related]
4. Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate.
Kondo S; Tanimoto K; Yamada K; Yoshimoto G; Suematsu E; Fujisaki T; Oshiro Y; Tamura K; Takeshita M; Okamura S
Virchows Arch; 2013 Apr; 462(4):399-407. PubMed ID: 23494713
[TBL] [Abstract][Full Text] [Related]
5. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.
Hoshida Y; Xu JX; Fujita S; Nakamichi I; Ikeda J; Tomita Y; Nakatsuka S; Tamaru J; Iizuka A; Takeuchi T; Aozasa K
J Rheumatol; 2007 Feb; 34(2):322-31. PubMed ID: 17117491
[TBL] [Abstract][Full Text] [Related]
6. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients.
Kameda T; Dobashi H; Miyatake N; Inoo M; Onishi I; Kurata N; Mitsunaka H; Kawakami K; Fukumoto T; Susaki K; Izumikawa M; Nakashima S; Shimada H; Takeuchi Y; Haba R; Mano S; Onishi H; Imataki O; Matsunaga T
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1302-9. PubMed ID: 24515570
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
Harada T; Iwasaki H; Muta T; Urata S; Sakamoto A; Kohno K; Takase K; Miyamura T; Sawabe T; Asaoku H; Oryoji K; Fujisaki T; Mori Y; Yoshimoto G; Ayano M; Mitoma H; Miyamoto T; Niiro H; Yamamoto H; Oshiro Y; Miyoshi H; Ohshima K; Takeshita M; Akashi K; Kato K
Br J Haematol; 2021 Jul; 194(1):101-110. PubMed ID: 33822354
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis.
Yoshida Y; Takahashi Y; Yamashita H; Kano T; Kaneko H; Mimori A
Mod Rheumatol; 2014 Sep; 24(5):763-5. PubMed ID: 24498893
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort.
Shimizu Y; Nakajima A; Inoue E; Shidara K; Sugimoto N; Seto Y; Tanaka E; Momohara S; Taniguchi A; Yamanaka H
Clin Rheumatol; 2017 Jun; 36(6):1237-1245. PubMed ID: 28455827
[TBL] [Abstract][Full Text] [Related]
10. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate.
Saito S; Kaneko Y; Yamaoka K; Tokuhira M; Takeuchi T
Rheumatology (Oxford); 2017 Jun; 56(6):940-946. PubMed ID: 28165538
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.
Ichikawa A; Arakawa F; Kiyasu J; Sato K; Miyoshi H; Niino D; Kimura Y; Takeuchi M; Yoshida M; Ishibashi Y; Nakashima S; Sugita Y; Miura O; Ohshima K
Eur J Haematol; 2013 Jul; 91(1):20-8. PubMed ID: 23560463
[TBL] [Abstract][Full Text] [Related]
12. Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders.
Nakano K; Saito K; Nawata A; Hanami K; Kubo S; Miyagawa I; Fujino Y; Nakayamada S; Tanaka Y
Mod Rheumatol; 2021 Jan; 31(1):94-100. PubMed ID: 32159414
[TBL] [Abstract][Full Text] [Related]
13. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: A review of the literature and current perspective.
Harigai M
Mod Rheumatol; 2018 Jan; 28(1):1-8. PubMed ID: 28758827
[TBL] [Abstract][Full Text] [Related]
14. Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis.
Tanaka K; Ichikawa A; Umezawa N; Yamamoto K; Yoshifuji K; Okada K; Nogami A; Umezawa Y; Nagao T; Sakashita C; Mori T; Tohda S; Koike R; Yasuda S; Yamamoto M
Cancer Sci; 2023 Sep; 114(9):3719-3727. PubMed ID: 37365854
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.
Salloum E; Cooper DL; Howe G; Lacy J; Tallini G; Crouch J; Schultz M; Murren J
J Clin Oncol; 1996 Jun; 14(6):1943-9. PubMed ID: 8656264
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression.
Takanashi S; Aisa Y; Ito C; Arakaki H; Osada Y; Amano Y; Hirano M; Nakazato T
Rheumatol Int; 2017 Oct; 37(10):1629-1633. PubMed ID: 28676912
[TBL] [Abstract][Full Text] [Related]
17. Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients.
Saito S; Takeuchi T
J Clin Exp Hematop; 2019; 59(4):145-155. PubMed ID: 31866617
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors.
Kurita D; Miyoshi H; Ichikawa A; Kato K; Imaizumi Y; Seki R; Sato K; Sasaki Y; Kawamoto K; Shimono J; Yamada K; Muto R; Kizaki M; Nagafuji K; Tamaru JI; Tokuhira M; Ohshima K
Am J Surg Pathol; 2019 Jul; 43(7):869-884. PubMed ID: 31116708
[TBL] [Abstract][Full Text] [Related]
19. Reversible methotrexate-associated lymphoproliferative disorder resembling advanced gastric cancer in a patient with rheumatoid arthritis.
Satoh K; Yoshida N; Imaizumi K; Yajima M; Wakui H; Sawada K; Komatsuda A
Am J Med Sci; 2009 Oct; 338(4):334-5. PubMed ID: 19745701
[TBL] [Abstract][Full Text] [Related]
20. Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: Results from a Japanese multi-institutional retrospective study.
Honda S; Sakai R; Inoue E; Majima M; Konda N; Takada H; Kihara M; Yajima N; Nanki T; Yamamoto K; Takeuchi T; Harigai M
Mod Rheumatol; 2022 Jan; 32(1):16-23. PubMed ID: 33428479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
